| Literature DB >> 32993146 |
Sayed Asmat Ali Shah1, Syed Shams Ul Hassan2,3, Simona Bungau4, Yongsheng Si1, Haiwei Xu1, Md Habibur Rahman5, Tapan Behl6, Daniela Gitea4, Flavia-Maria Pavel7, Raluca Anca Corb Aron7, Bianca Pasca4, Sebastian Nemeth4.
Abstract
For a long time, algal chemistry from terrestrial to marine or freshwater bodies, especially chlorophytes, has fascinated numerous investigators to develop new drugs in the nutraceutical and pharmaceutical industries. As such, chlorophytes comprise a diverse structural class of secondary metabolites, having functional groups that are specific to a particular source. All bioactive compounds of chlorophyte are of great interest due to their supplemental/nutritional/pharmacological activities. In this review, a detailed description of the chemical diversity of compounds encompassing alkaloids, terpenes, steroids, fatty acids and glycerides, their subclasses and their structures are discussed. These promising natural products have efficiency in developing new drugs necessary in the treatment of various deadly pathologies (cancer, HIV, SARS-CoV-2, several inflammations, etc.). Marine chlorophyte, therefore, is portrayed as a pivotal treasure in the case of drugs having marine provenience. It is a domain of research expected to probe novel pharmaceutically or nutraceutically important secondary metabolites resulting from marine Chlorophyta. In this regard, our review aims to compile the isolated secondary metabolites having diverse chemical structures from chlorophytes (like Caulerpa ssp., Ulva ssp., Tydemania ssp., Penicillus ssp., Codium ssp., Capsosiphon ssp., Avrainvillea ssp.), their biological properties, applications and possible mode of action.Entities:
Keywords: alkaloids; chlorophytes; fatty acid; glycerides; lipids; steroids; terpenes
Mesh:
Substances:
Year: 2020 PMID: 32993146 PMCID: PMC7601752 DOI: 10.3390/md18100493
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structural diversity of compounds produced by Chlorophyta.
Figure 2Diagrammatic process of inflammatory cascade inside the cell. Phospholipase A2 (PLA2) catalyzes the release of membrane-bound arachidonic acid (AA) to free arachidonic acid. Arachidonic acid is then converted to leukotrienes and prostaglandins by lipoxygenase (LOX) and cyclooxygenase-2 (COX-2), respectively. Alkaloidal substances inhibit inflammation by different targets mentioned in the cascade.
Figure 3The names of Compounds 1–17 are represented in Table 1.
Alkaloids and prenylated compounds from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| Racemosin A ( |
| Neuroprotective | [ |
| Racemosin B ( |
| Neuroprotective | [ |
| Racemosin C ( |
| Significant PTP1B inhibitor | [ |
| Caulerpin ( | Strong PTP1B inhibitor | [ | |
| Caulersin ( |
| PTP1B inhibitor | [ |
| Caulerchlorin ( |
| Weak antifungal | [ |
| Caulerprenylols A ( |
| Antifungal | [ |
| Caulerprenylols B ( |
| Antifungal | [ |
| Pyrrolopipera-zine-2,5-dione ( |
| Antialgal | [ |
| 7-Hydroxycymo-pochromanone (PBQI) ( |
| Chemotherapeutic | [ |
| 7-Hydroxycymo-polone (PBQ2) ( |
| Chemotherapeutic, Anticancer colon cell | [ |
| 3′-methoxy-7-hydroxycymopolone ( |
| Antimutagenic against | [ |
| 3-hydroxycymopolone ( |
| Antimutagenic against | [ |
| 3,7-hydroxycymopolone ( |
| Antimutagenic against | [ |
| 7-dihydroxycymo-pochromenol ( |
| Antimutagenic against | [ |
| Derivatives of cymopochromenol ( |
| Antimutagenic- | [ |
Figure 4In cancerous cells, STAT3 phosphorylates by JAKs (1). Activated STAT3 moves towards the cell’s nucleus (2) and prevents the transcription of SHP1 (3) which results in the reduction of protein level (4). Overexpressing SHP1 via some of its agonists (7) results in the dephosphorylation of STAT3 (6) and also JAKs (8) to reduce the protein level (9). That results in the apoptosis of the cancer cell (10). Abbreviations: Extracellular growth factor (EGF), receptor tyrosine kinase (RTK), Src homology domain-containing protein tyrosine phosphatase (SHP-1), Janus-associated kinase (JAK), signal transducer and activator of transcription 3 (STAT3).
Sesquiterpene metabolites derived from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| Caulerpal A ( |
| hPTP1B inhibitor | [ |
| Caulerpal B ( |
| hPTP1B inhibitor | [ |
| Acetylene Sesquiterpenoid Esters ( |
| Antibacterial | [ |
| Acetylene Sesquiterpenoid Esters ( |
| Antibacterial | [ |
| Guai-2-en-10α-ol ( |
| Antibacterial | [ |
| guai-2-en-10α-methanol ( |
| Antibacterial | [ |
| Guai-2-en-10α-methyl methanoate ( |
| Antibacterial | [ |
Figure 5The names of compounds are given as 20–34 in Table 2.
Figure 6The names of compounds are represented as 38–47 in Table 3.
Diterpenoids metabolites derived from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| labda-14-ene-8-ol ( |
| Antibacterial | [ |
| labda-14-ene-3α,8α-diol ( |
| Antibacterial | [ |
| labda-14-ene-8α,9α-diol ( |
| Antibacterial | [ |
| labda-14-ene-8α-hydroxy-3-one ( |
| Antibacterial | [ |
| ent-labda-13(16),14-diene-2-one ( |
| Antibacterial | [ |
| ent-labda-13(16),14-diene-3α-ol ( |
| Antibacterial | [ |
| ent-labda-13(16),14-diene-3α-ol ( |
| Antibacterial | [ |
| racemobutenolids A, B ( |
| - | [ |
| 4,5-dehydrodiodictyonema A ( |
| PTP1B inhibitor | [ |
| an α-tocopheroid,α-tocoxylenoxy ( |
| PTP1B inhibitor | [ |
Figure 7The names of compounds are represented as 48–54 in Table 4.
Terpenoid metabolites derived from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| Lanosta-8-en-3,29-diol-23-oxo-3,29-disodium sulfate ( |
| cytotoxic tumor cell | [ |
| Capisterones A ( |
| potent antifungal | [ |
| Capisterones B ( |
| potent antifungal | [ |
| Squalene ( |
| - | [ |
| Dwarkenoic acid ( |
| alpha-glucosidase inhibitor | [ |
| Loliolide ( |
| - | [ |
| Lsololiolide ( |
| - | [ |
Figure 8The names of compounds are denoted as 55–73 in Table 5.
Steroids and fatty acid metabolites derived from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| Cholest-5-en-3-ol ( |
| Antialgal | [ |
| (8 |
| - | [ |
| Hexadeca-4,7,10,13-tetraenoic acid (HDTA) ( |
| Algicidal | [ |
| Octadeca-6,9,12,15-tetraenoic acid (ODTA) ( |
| Algicidal | [ |
| α-linolenic acid ( |
| Algicidal | [ |
| β-sitosterol ( |
| - | [ |
| (1, iyengadione) ( |
| - | [ |
| iyengaroside-A ( |
| Antibacterial | [ |
| Clerosterol galactoside ( |
| - | [ |
| 3-hydroxy-octadeca-4( |
| Antitumor | [ |
| 3-hydroxyhexadeca-4( |
| Antitumor | [ |
| (24 |
| Aldose reductase inhibitor | [ |
| (24 |
| Aldose reductase inhibitor | [ |
| 24 |
| Aldose reductase inhibitor | [ |
| keto-type fatty acid ( |
| ARE activators | [ |
| Shorter chain C16 acid ( |
| ARE activators | [ |
| Amide derivative ( |
| ARE activators | [ |
| (23 |
| PTP1B inhibitor | [ |
Figure 9The names of compounds are represented as 74–85 in Table 6.
Glycerol and lipids metabolites derived from Chlorophyta.
| Compound | Species | Bioactivity | Ref. |
|---|---|---|---|
| 1- |
| Antialgal | [ |
| 1- |
| Antialgal | [ |
| 1- |
| Antialgal | [ |
| Monopalmitate ( |
| Antialgal | [ |
| 9-hexadecenoic acid, 2,3-dihydroxypropyl ester ( |
| Antialgal | [ |
| 1-eicosapentaenoyl-2-linolenoyl-3-galacto-sylglycerol ( |
| Anti-inflammatory | [ |
| Capsofulvesins ( |
| Acetylcholinesterase (ache) inhibitor | [ |
| Galactosylglycerolipid |
| - | [ |
| Sulfoquinovosyl diacylglycerol (SQDG) ( |
| Antiviral against HSV-2 | [ |
| Avrainvilloside ( |
| Inactive cytotoxic | [ |
Figure 10Properties and applications of green algae.